PubRank

Federico Cappuzzo

Author PubWeight™ 129.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 32.68
2 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010 13.25
3 First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014 10.91
4 Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010 6.39
5 Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012 5.28
6 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011 4.51
7 Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011 2.98
8 Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012 2.66
9 Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011 2.32
10 Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008 1.92
11 Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010 1.85
12 HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006 1.83
13 Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005 1.69
14 EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 2011 1.57
15 Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 2013 1.50
16 Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 2009 1.44
17 Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer 2007 1.37
18 Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 2006 1.31
19 Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev 2007 1.21
20 Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 2006 1.18
21 Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009 1.15
22 Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int 2012 1.07
23 Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 2012 1.06
24 Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol 2013 1.03
25 Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials 2006 1.03
26 ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med 2014 1.03
27 Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics 2013 1.01
28 Emerging drugs for small cell lung cancer--an update. Expert Opin Emerg Drugs 2012 0.96
29 Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist 2010 0.96
30 Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004 0.96
31 Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? J Natl Cancer Inst 2005 0.95
32 Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. J Clin Pathol 2011 0.94
33 Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008 0.93
34 Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol 2011 0.93
35 Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010 0.92
36 Primary pulmonary meningioma: report of a case and review of the literature. Lung Cancer 2008 0.92
37 Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer 2012 0.90
38 Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. Cancer Cytopathol 2014 0.90
39 Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Curr Opin Oncol 2013 0.90
40 HER2 and lung cancer. Expert Rev Anticancer Ther 2013 0.88
41 Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer 2013 0.88
42 HER2 in solid tumors: more than 10 years under the microscope; where are we now? Future Oncol 2014 0.87
43 Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother 2014 0.86
44 Targeted therapy for NSCLC with driver mutations. Expert Opin Biol Ther 2013 0.86
45 Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther 2009 0.86
46 Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 2013 0.85
47 Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2007 0.85
48 Emerging drugs for small-cell lung cancer. Expert Opin Emerg Drugs 2009 0.85
49 Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. Nat Rev Clin Oncol 2011 0.85
50 Onartuzumab in lung cancer: the fall of Icarus? Expert Rev Anticancer Ther 2015 0.83
51 Impact of biomarkers on non-small cell lung cancer treatment. Target Oncol 2010 0.83
52 Gefitinib for non-small-cell lung cancer treatment. Expert Opin Drug Saf 2011 0.82
53 Management of NSCLC: focus on crizotinib. Expert Opin Pharmacother 2014 0.82
54 Present and future treatment of advanced non-small cell lung cancer. Semin Oncol 2002 0.81
55 Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol 2014 0.81
56 Rare mutations in non-small-cell lung cancer. Future Oncol 2013 0.80
57 Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opin Pharmacother 2014 0.80
58 Erlotinib in the first-line treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 2013 0.80
59 Gemcitabine in non-small cell lung cancer. Expert Opin Pharmacother 2002 0.77
60 Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature? Hum Pathol 2010 0.75
61 Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference? J Thorac Dis 2012 0.75
62 Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer 2010 0.75
63 Is gemcitabine cost effective in cancer treatment? Expert Rev Pharmacoecon Outcomes Res 2007 0.75
64 EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients? Expert Opin Med Diagn 2007 0.75
65 The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? Curr Drug Targets 2014 0.75
66 Should every lung cancer patient be tested for EGFR mutation? Expert Opin Ther Targets 2006 0.75
67 New platinum derivatives in advanced non-small cell lung cancer. Suppl Tumori 2002 0.75